Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

被引：0
|
作者：
Weiwei Huang
Chenxi Wang
Yangkun Shen
Qi Chen
Zhijian Huang
Jian Liu
Xiaoyan Lin
Lili Wang
Fan Wu
Xinhua Chen
Nani Li
Yi Hong
Mulan Chen
Jieyu Li
Chuanzhong Huang
机构：
[1] Fujian Medical University Union Hospital,Department of Medical Oncology
[2] Clinical Oncology School of Fujian Medical University,Department of Medical Oncology
[3] Fujian Cancer Hospital,Fujian Key Laboratory of Translational Cancer Medicine
[4] Fujian Cancer Hospotial,Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China
[5] Fujian Normal University Qishan Campus,Department of Breast Surgical Oncology
[6] Clinical Oncology School of Fujian Medical University,Laboratory of Immuno
[7] Fujian Cancer Hospital,Oncology
[8] Clinical Oncology School of Fujian Medical University,undefined
[9] Fujian Cancer Hospital,undefined
来源：
BMC Cancer | / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study
    Du, Yingying
    Cao, Qisheng
    Jiang, Congqiao
    Liang, Hui
    Ning, Zhongliang
    Ji, Chushu
    Wang, Jinguo
    Zhou, Chaoping
    Jiang, Zonghui
    Yu, Changjun
    Li, Lei
    Zhao, Yong
    Xu, Yuemei
    Xu, Tengyun
    Hu, Wenjun
    Wang, Daoqin
    Cheng, Huaidong
    Wang, Guihe
    Zhou, Jinhua
    Wang, Song
    Zhang, Yanshun
    Hu, Zhiqiang
    Li, Xinzhong
    Lu, Donghui
    Zhang, Jun
    Xie, Hua
    Sun, Guoping
    CANCER MEDICINE, 2020, 9 (14): : 5008 - 5014
  • [32] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Qingyuan Zhang
    Bin Shao
    Zhongsheng Tong
    Quchang Ouyang
    Yuting Wang
    Guoying Xu
    Shaorong Li
    Huiping Li
    BMC Medicine, 20
  • [33] Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
    Celik, Alan
    Berg, Tobias
    Jensen, Maj-Britt
    Jakobsen, Erik
    Nielsen, Hanne Melgaard
    Kumler, Iben
    Glavicic, Vesna
    Jensen, Jeanette Dupont
    Knoop, Ann
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17
  • [34] Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
    Olsson, Erik
    Lindman, Henrik
    Digkas, Evangelos
    Thurfjell, Viktoria
    Ali, Haidar Mir
    Kruger, Ute
    Wennstig, Anna-Karin
    Sundqvist, Marie
    Valachis, Antonios
    BREAST, 2025, 79
  • [35] A real-world multicentre retrospective study of low-dose apatinib for HER2-negative metastatic breast cancer
    Zeng, Tianyu
    Li, Wei
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2021, 32 : S319 - S319
  • [36] Atezolizumab for metastatic triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (10): : E519 - E519
  • [37] Iniparib in Metastatic Triple-Negative Breast Cancer
    Domagala, Pawel
    Lubinski, Jan
    Domagala, Wenancjusz
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18): : 1780 - 1780
  • [38] Treatment of Metastatic Triple-Negative Breast Cancer
    Glendenning, Jennifer
    Irshad, Sheeba
    Tutt, Andrew
    CURRENT BREAST CANCER REPORTS, 2012, 4 (01) : 10 - 21
  • [39] Treatment of Metastatic Triple-Negative Breast Cancer
    Jennifer Glendenning
    Sheeba Irshad
    Andrew Tutt
    Current Breast Cancer Reports, 2012, 4 (1) : 10 - 21
  • [40] Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study
    Fan, Wei
    Ding, Jun
    Zhong, Wei
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 260 (01): : 13 - 20
12345